P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847968.95263.25 |
| _version_ | 1797285845399502848 |
|---|---|
| author | M. K. Leabman G. Hernandez C. M. Ng J. Tang D. Pandya K. C. Hart K. Li P. R. Hinton J. So I. Qazi C. Y. Cheah W. S. Kim E. Budde A. K. Gopal T. Manley C. H. Takimoto A. M. Sinclair S. F. Carroll B. A. Keyt M. F. Kotturi |
| author_facet | M. K. Leabman G. Hernandez C. M. Ng J. Tang D. Pandya K. C. Hart K. Li P. R. Hinton J. So I. Qazi C. Y. Cheah W. S. Kim E. Budde A. K. Gopal T. Manley C. H. Takimoto A. M. Sinclair S. F. Carroll B. A. Keyt M. F. Kotturi |
| author_sort | M. K. Leabman |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:09:11Z |
| format | Article |
| id | doaj.art-0b096a9e042e4b0d89131ab7c9e7b9c8 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:09:11Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-0b096a9e042e4b0d89131ab7c9e7b9c82024-03-02T07:47:25ZengWileyHemaSphere2572-92412022-06-0161161116210.1097/01.HS9.0000847968.95263.25202206003-01161P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMAM. K. Leabman0G. Hernandez1C. M. Ng2J. Tang3D. Pandya4K. C. Hart5K. Li6P. R. Hinton7J. So8I. Qazi9C. Y. Cheah10W. S. Kim11E. Budde12A. K. Gopal13T. Manley14C. H. Takimoto15A. M. Sinclair16S. F. Carroll17B. A. Keyt18M. F. Kotturi191 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America2 Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia3 Samsung Medical Center, Seoul, South Korea4 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte5 University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of America1 IGM Biosciences, Inc., Mountain View, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847968.95263.25 |
| spellingShingle | M. K. Leabman G. Hernandez C. M. Ng J. Tang D. Pandya K. C. Hart K. Li P. R. Hinton J. So I. Qazi C. Y. Cheah W. S. Kim E. Budde A. K. Gopal T. Manley C. H. Takimoto A. M. Sinclair S. F. Carroll B. A. Keyt M. F. Kotturi P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA HemaSphere |
| title | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_full | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_fullStr | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_full_unstemmed | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_short | P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA |
| title_sort | p1276 dose response profile of igm 2323 a cd20xcd3 igm bispecific t cell engager in translational models supports phase 2 dose selection in non hodgkin s lymphoma |
| url | http://journals.lww.com/10.1097/01.HS9.0000847968.95263.25 |
| work_keys_str_mv | AT mkleabman p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT ghernandez p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT cmng p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT jtang p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT dpandya p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT kchart p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT kli p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT prhinton p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT jso p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT iqazi p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT cycheah p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT wskim p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT ebudde p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT akgopal p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT tmanley p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT chtakimoto p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT amsinclair p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT sfcarroll p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT bakeyt p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma AT mfkotturi p1276doseresponseprofileofigm2323acd20xcd3igmbispecifictcellengagerintranslationalmodelssupportsphase2doseselectioninnonhodgkinslymphoma |